Name: Monthly Cumulative Number And Percent Of Children <8 Months Who Received Nirsevimab By Jurisdiction, United States
Creator: US Centers for Disease Control and Prevention
License: https://www.cdc.gov/other/agencymaterials.html

CDC - Vaccinations

Monthly Cumulative Percent of Children <8 Months Who Received Nirsevimab by Jurisdiction, United States.
Nirsevimab coverage for children 0 to 7 months is assessed through U.S. jurisdictions’ Immunization Information Systems Resources (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group (https://www.cdc.gov/iis/about/).

Tags: iis, nis-acm, vsd, iqvia, rsv vaccination

Last updated: 2024-11-20 17:38:21+00:00

Related Datasets

Monthly Cumulative Number And Percent Of Children <20 Months Who Received Nirsevimab By Age Group And Jurisdiction, United States

@cdc
Monthly Cumulative Number And Percent Of Adults 75 Years And Older Who Received 1+ RSV Vaccination Doses By Jurisdiction, United States

@cdc
Monthly Cumulative Number And Percent Of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses And Comparison Between 2024-25 And 2023-24 Seasons, By Age Group And Jurisdiction, United States

@cdc
Monthly Cumulative Number And Percent Of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses, By Age Group, And Jurisdiction, United States

@cdc
Infant Protection Against Respiratory Syncytial Virus (RSV) By Maternal RSV Vaccination Or Receipt Of Nirsevimab, And Intent For Nirsevimab Receipt, United States

@cdc
Monthly Nirsevimab Receipt And Intent Among Females Aged 18-49 Years Who Have A Baby <8 Months, Are Currently Pregnant, Or Are Trying To Get Pregnant, United States

@cdc

Monthly Cumulative Number And Percent Of Children <20 Months Who Received Nirsevimab By Age Group And Jurisdiction, United States

Monthly Cumulative Number And Percent Of Adults 75 Years And Older Who Received 1+ RSV Vaccination Doses By Jurisdiction, United States

Monthly Cumulative Number And Percent Of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses And Comparison Between 2024-25 And 2023-24 Seasons, By Age Group And Jurisdiction, United States

Monthly Cumulative Number And Percent Of Persons Who Received 1+ 2024-25 COVID-19 Vaccination Doses, By Age Group, And Jurisdiction, United States

Infant Protection Against Respiratory Syncytial Virus (RSV) By Maternal RSV Vaccination Or Receipt Of Nirsevimab, And Intent For Nirsevimab Receipt, United States

Monthly Nirsevimab Receipt And Intent Among Females Aged 18-49 Years Who Have A Baby <8 Months, Are Currently Pregnant, Or Are Trying To Get Pregnant, United States